What are the recommended pediatric dosing regimens for cefazolin and clindamycin?

Pediatric Dosing for Cefazolin and Clindamycin

For cefazolin, use 150 mg/kg/day divided every 8 hours (50 mg/kg/dose) for methicillin-susceptible Staphylococcus aureus infections, and for clindamycin, use 40 mg/kg/day divided every 6-8 hours for parenteral therapy or 30-40 mg/kg/day divided into 3-4 doses for oral therapy.

Cefazolin Dosing

Standard Dosing by Indication

For methicillin-susceptible S. aureus (MSSA) infections:

• Parenteral: 150 mg/kg/day divided every 8 hours 1, 2, 1
• Oral step-down: Cephalexin 75-100 mg/kg/day in 3-4 doses 1

For mild to moderate infections:

• Total daily dose: 25-50 mg/kg/day divided into 3-4 equal doses 3
• For severe infections: May increase to 100 mg/kg/day 3

Dosing by Weight (FDA Label)

For 25 mg/kg/day regimen divided every 8 hours 3:

• 10 lb (4.5 kg): 40 mg every 8 hours
• 20 lb (9 kg): 75 mg every 8 hours
• 30 lb (13.6 kg): 115 mg every 8 hours
• 40 lb (18.1 kg): 150 mg every 8 hours
• 50 lb (22.7 kg): 190 mg every 8 hours

For 50 mg/kg/day regimen divided every 8 hours 3:

• 10 lb (4.5 kg): 75 mg every 8 hours
• 20 lb (9 kg): 150 mg every 8 hours
• 30 lb (13.6 kg): 225 mg every 8 hours
• 40 lb (18.1 kg): 300 mg every 8 hours
• 50 lb (22.7 kg): 375 mg every 8 hours

Renal Impairment Adjustments

After initial loading dose 3:

• CrCl 70-40 mL/min: 60% of normal daily dose divided every 12 hours
• CrCl 40-20 mL/min: 25% of normal daily dose divided every 12 hours
• CrCl 20-5 mL/min: 10% of normal daily dose every 24 hours

Critical Considerations

Not recommended for premature infants and neonates - safety not established 3. Recent research shows that weight-based dosing may be inadequate during cardiopulmonary bypass, where additional dosing based on circuit priming volume (≥30 mg per 100 mL) is necessary 4.

Clindamycin Dosing

Parenteral (IV) Dosing

For serious infections:

• 40 mg/kg/day divided every 6-8 hours for most bacterial infections 1, 2, 1
• This applies to Group A Streptococcus, resistant S. pneumoniae, and MRSA (when susceptible) 1

Oral Dosing

For step-down or mild infections:

• 30-40 mg/kg/day divided into 3-4 doses 1, 2, 1
• Specifically 40 mg/kg/day in 3 doses for Group A Streptococcus 1

FDA-approved oral dosing 5:

• Serious infections: 8-16 mg/kg/day divided into 3-4 equal doses
• More severe infections: 16-20 mg/kg/day divided into 3-4 equal doses
• Must be able to swallow capsules whole; use palmitate oral solution if unable

Special Populations

For neonates and young infants (based on postmenstrual age) 6:

• ≤32 weeks PMA: Lower doses required due to immature clearance
• Clearance reaches 50% of adult value at 39.5 weeks PMA
• Dose based on total body weight regardless of obesity 5

For musculoskeletal infections in MRSA-prevalent communities:

• 30 mg/kg/day oral dosing has proven effective as an alternative to 40 mg/kg/day 7
• Average outpatient treatment duration: approximately 33 days 7

Important Clinical Caveats

Clindamycin Resistance Warning

Clindamycin resistance is increasing in certain geographic areas among both S. pneumoniae and S. aureus 1. Always verify local susceptibility patterns before selecting clindamycin as definitive therapy.

Administration Requirements

Cefazolin:

• Reconstitute and shake well before administration 3
• For IV bolus: Inject slowly over 3-5 minutes 3
• Stable for 24 hours at room temperature or 10 days refrigerated 3

Clindamycin:

• Must take with full glass of water to avoid esophageal irritation 5
• Not suitable for children unable to swallow capsules whole 5
• If significant diarrhea occurs, discontinue immediately (C. difficile risk) 5

Duration of Therapy

For β-hemolytic streptococcal infections, continue treatment for at least 10 days 5. CA-MRSA infections may require longer treatment courses than S. pneumoniae infections 1.

Surgical Prophylaxis Context

When used for surgical prophylaxis, cefazolin is strongly preferred over clindamycin. Recent evidence shows clindamycin prophylaxis increases surgical site infection risk 2.5-fold compared to cefazolin in clean craniotomy 8, and adverse reactions are 7 times more likely with clindamycin versus cefazolin 9. Even in patients with penicillin allergy labels, cefazolin can often be safely administered based on reaction type risk stratification 10.